Evidence map›Paper›PMID 24206135›Full record

ReviewCurrent molecular medicine2013

Fluorescent molecular imaging: technical progress and current preclinical and clinical applications in urogynecologic diseases.

V M Alexander, P L Choyke, H Kobayashi

Abstract readReview
In one paragraph

Review in Current molecular medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

V M AlexanderMolecular Imaging Program, NCI/NIH, Building 10, Room B3B69, MSC 1088, Bethesda, Maryland 20892-1088, USA. pchoyke@mail.nih.gov.
P L Choyke
H Kobayashi

Funding

Activatable molecular cancer imaging probeZIABC011512 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KOBAYASHI, HISATAKA · 2013 to 2025
$2.7M
Lymphatic ImagingZ01BC010654 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CHOYKE, PETER L · 2005 to 2008
$1.1M
Intramural NIH HHS Z01 BC010654Intramural NIH HHS ZIA BC011512
6 · The paper itself

Abstract

Many molecular imaging probes have been developed in recent years that hold great promise for both diagnostic and therapeutic functions in urogynecologic disease. Historically, optical probe designs were based on either endogenous or exogenous fluorophores. More recently, organic fluorophore probes have been engineered to target specific tissues and emit fluorescence only upon binding to targets. Several different photochemical mechanisms of activation exist. This review presents a discussion of the history and development of molecular imaging probe designs and provides an overview of successful preclinical and clinical models employing molecular probes for in vivo imaging of urogynecologic cancers.

Indexed as

Fluorescent DyesMolecular ImagingMolecular ProbesAnimalsFemaleFemale Urogenital DiseasesFluorescenceHumansMaleMale Urogenital DiseasesFluorescent DyesMolecular Probes

Identifiers

PMID24206135
PMCPMC7511996

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.